The SHBG-like region of protein S is crucial for factor V-dependent APC-cofactor function  by Nyberg, Petra et al.
The SHBG-like region of protein S is crucial for factor V-dependent
APC-cofactor function
Petra Nyberg, Bjoºrn Dahlbaºck*, Pablo Garc|Ła de Frutos
Department of Clinical Chemistry, Wallenberg Laboratory, Lund University, University Hospital, S-20502 Malmoº, Sweden
Received 8 June 1998
Abstract Activated protein C (APC) regulates blood coagula-
tion by degrading factor Va (FVa) and factor VIIIa (FVIIIa).
Protein S is a cofactor to APC in the FVa degradation, whereas
FVIIIa degradation is potentiated by the synergistic APC-
cofactor activity of protein S and factor V (FV). To elucidate the
importance of the sex-hormone-binding globulin (SHBG)-like
region in protein S for expression of anticoagulant activity, a
recombinant protein S/Gas6 chimera was constructed. It
comprised the amino-terminal half of protein S and the SHBG-
like region of Gas6, a structurally similar protein having no
known anticoagulant properties. The protein S/Gas6 chimera
expressed 40^50% APC-cofactor activity in plasma as compared
to wild-type protein S. In the degradation of FVa by APC, the
protein S/Gas6 chimera was only slightly less efficient than wild-
type protein S. In contrast, the protein S/Gas6 chimera expressed
no FV-dependent APC-cofactor activity in a FVIIIa-degradation
system. This demonstrates the SHBG-like region to be important
for expression of APC-cofactor activity of protein S and suggests
that the SHBG-like region of protein S interacts with FV during
the APC-mediated inactivation of FVIIIa.
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1. Introduction
The protein C anticoagulant pathway is essential for main-
taining the hemostatic balance, as illustrated by the associa-
tion between venous thrombosis and genetic defects a¡ecting
the pathway [1,2]. Protein C is activated by thrombin bound
to thrombomodulin on the surface of vascular endothelium,
and activated protein C (APC) inhibits coagulation by cleav-
ing and inactivating phospholipid-bound activated factor V
(FVa) and factor VIII (FVIIIa). In the degradation of FVa,
APC e⁄ciently cleaves FVa at position Arg-506, whereas FVa
cleavage at Arg-306 requires the presence of protein S, which
functions as an APC cofactor [3]. Cleavage of FVa at Arg-506
results in partial loss of FVa activity, but full FVa inhibition
requires cleavage at both Arg-506 and Arg-306. The APC-
mediated degradation of FVIIIa appears to be more complex
than that of FVa. APC alone is ine⁄cient in inhibiting the
activity of the FVIIIa-FIXa (factor IXa) complex. Protein S
increases the e⁄ciency of APC only slightly, and full inacti-
vation of FVIIIa requires the presence of yet another protein
cofactor, namely factor V (FV) [4^6]. FV has been found to
potentiate the APC-mediated inhibition of FVIIIa both in
plasma and in puri¢ed systems. Full expression of anticoagu-
lant activity of FV is dependent on the presence of protein S
and the two proteins appear to function as synergistic APC
cofactors [4^6].
Human protein S is a 635 amino acid long multidomain
protein, composed of a Q-carboxyglutamic acid-containing
(Gla) domain, a thrombin-sensitive region (TSR), four epider-
mal growth factor (EGF)-like domains and a region which is
homologous to sex-hormone-binding globulin (SHBG) [7].
The Gla domain is required for binding of protein S to phos-
pholipid membranes. Studies using speci¢c monoclonal anti-
bodies [8], human-bovine chimeras [9], or recombinant EGF-
like domains [10] have demonstrated the TSR and EGF1 to
be important for expression of the APC-cofactor function.
This is consistent with the observation that a protein S dele-
tion mutant, ‘mini-protein S’ lacking the whole SHBG-like
region, is able to function as an APC cofactor [11]. However,
mini-protein S did not demonstrate full APC-cofactor activity
in a plasma system, possibly indicating the SHBG-like region
to be required for full APC-cofactor function [11].
To elucidate the importance of the SHBG-like region of
protein S for expression of APC-cofactor activity, a recombi-
nant protein S/Gas6 chimeric protein was expressed and used
in a series of functional assays. Gas6 (the product of growth-
arrest-speci¢c gene 6, gas6 [12]) is homologous to protein S,
sharing 44% amino acid identity and similar modular compo-
sition [13]. Gas6 is a ligand for the Axl subfamily of tyrosine
kinase receptors [14] and a¡ects cell growth, mitogenic activity
and apoptosis [15,16]. While protein S has been suggested to
stimulate some of these receptors [17^19], Gas6 is not known
to play any role in anticoagulation. We now wish to report
that the SHBG-like region of protein S is crucial for the FV-
dependent APC-cofactor function expressed during inactiva-
tion of FVIIIa.
2. Materials and methods
2.1. Materials
Phospholipid vesicles composed of 25% (w/w) phosphatidylserine,
37.5% (w/w) phosphatidylcholine and 37.5% (w/w) phosphatidyletha-
nolamine were prepared as described [20]. Simplastin Excel (thrombo-
plastin reagent) and FV-de¢cient (immuno-depleted) plasma were pur-
chased from Organon Teknika and Biopool, respectively. Human
protein C was puri¢ed from plasma and activated as described [21].
Protein S, FV, FVa, and a-thrombin (all of human origin) were pur-
chased from Haematologic Technologies Inc. Human FVIII (Octona-
tive M) was from Pharmacia and hirudin from Sigma. Puri¢ed bovine
factors X and IXa, chromogenic substrate S-2222 and the Coatest
APC Resistance kit were kindly provided by Chromogenix. Protein
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S-depleted plasma was prepared as previously described [22], but with
monoclonal antibody HPS54 [8], coupled to A⁄gel-10 (Bio-Rad),
replacing the immobilized polyclonal anti-protein S antibodies. The
concentration of FVIII in the protein S-de¢cient plasma was adjusted
to 1 IU/ml using Octonative M.
2.2. Recombinant proteins
The full-length human protein S cDNA [7] was subcloned into the
BamHI site of the expression vector pcDNA3 (Invitrogen). The pro-
tein S/Gas6 chimera was obtained by recombinant PCR techniques
[23] using protein S and Gas6 (a kind gift from Dr. Claudio
Schneider) cDNAs as templates. Two PCRs were initially performed
using the primer combinations A+B and C+D. Primer A, 5P-CGG
GAT CCA TGA GGG TCC TGG GTG G-3P (BamHI site under-
lined), corresponds to the 5P-part of protein S, whereas primer B, 5P-
GCA CGG CAA GAT GTC CTC ACA ACT CTT CTG-3P (Gas6
sequence underlined) is an antisense hybrid between protein S and
Gas6 sequences. Primers C, 5P-CAG AAG AGT TGT GAG GAC
ATC TTG CCG TGC-3P (protein S sequence underlined) is comple-
mentary to primer B. Primer D, 5P-CGG GAT CCT CGG ACA
GAG ACT GAG AA-3P (BamHI site underlined) corresponds to
the antisense strand of the 3P-part of Gas6. The human protein S
sequence ends at nucleotide 995 [24], corresponding to Glu-242 of
mature protein S, whereas the Gas6 starts at nucleotide 969 [13],
corresponding to Asp-231 of the mature Gas6. The two PCR products
were then used as templates together with primers A and D to create
the protein S/Gas chimera. After BamHI cleavage the construct was
subcloned in the pcDNA3 vector and the nucleotide sequence was
con¢rmed by dideoxy sequencing, using a sequencing kit from Per-
kin-Elmer. The full-length cDNA of human Gas6 was subcloned into
the EcoRI site of pcDNA3. Human kidney 293 cells were stably trans-
fected with the three vectors, containing protein S, Gas6 or the pro-
tein S/Gas6 chimeras, using Lipofectin (Life Technologies). The neo-
mycin analogue G418 (400 Wg/ml) was used for selection of
transfected cells. Colonies of resistant cells giving the highest expres-
sion level, according to immuno blotting, were chosen for further
expression. A mock transfection was carried out in parallel, using
pcDNA3 without an insert. Cells were cultured in Dulbecco’s modi-
¢ed Eagle’s medium (Gibco) supplemented with 10% (v/v) fetal calf
serum, 3.5 mM glutamine, 44 IU penicillin, 44 WM streptomycin and
10 Wg/ml vitamin K1. The medium was to changed to Optimem Glu-
tamax (Gibco) supplemented with 10 Wg/ml vitamin K1, 72 h prior to
collection. The recombinant protein S and the protein S/Gas6 chimera
were each puri¢ed from 2 l of culture medium using techniques de-
scribed previously [9]. The total amount of each protein obtained was
around 3 mg and the exact concentration was determined from the
amino acid composition after 24 h of hydrolysis in 6 M HCl in vacuo.
2.3. Electrophoretic and blotting techniques
Proteins subjected to 10% SDS-PAGE were either detected by Coo-
massie brilliant blue R-250 or transferred to polyvinylidene di£uoride
membrane (Millipore) for Western blotting. After transfer, mem-
branes were quenched with 50 mM Tris-HCl, 150 mM NaCl, pH
7.5, containing 3% (v/v) ¢sh gelatin and 0.1% (v/v) Tween 20, and
then incubated with the di¡erent antibodies diluted in the same bu¡er.
The membranes were rinsed with bu¡er without ¢sh gelatin and then
incubated with anti-immunoglobulins (DAKO) conjugated with
horseradish peroxidase. Immunoreactive bands were visualized by en-
hanced chemiluminescence (ECL) and the ¢lms were analyzed using a
Personal densitometer SI (Molecular Dynamics). Polyclonal antibod-
ies against the 25 C-terminal amino acids of human Gas6 were ob-
tained in rabbits using a technique previously described for a receptor-
derived peptide [18]. The Ca2-dependent monoclonal antibody
HPS21, against the Gla domain of unreduced human protein S, has
previously been characterized [8].
2.4. APC-cofactor activity expressed by protein S or the protein S/Gas6
chimera in a plasma-APTT system
In a modi¢ed APTT test [25], protein S-de¢cient plasma (50 Wl) was
mixed with recombinant protein S or the protein S/Gas6 chimera (10
Wl). The cofactors were diluted in TBS (50 mM Tris-HCl, 150 mM
NaCl, pH 7.5) containing 1% ovalbumin. The APTT reagent (50 Wl of
the APTT reagent present in the Coatest APC Resistance kit) was
added and the mixture incubated at 37‡ for 180 s. The reaction was
started by the addition of APC (approximately 6 nM) in 25 mM
CaCl2 (50 Wl of the APC/CaCl2 mixture present in the Coatest APC
Resistance kit) and the clotting time recorded.
2.5. APC-cofactor activity expressed by protein S or the protein S/Gas6
chimera in FVa degradation
FVa (30 nM), phospholipids (20 WM) and protein S or the protein
S/Gas6 chimera were incubated with human APC (0.3 nM) at 37‡C in
TBS containing 0.05% ovalbumin and 2 mM Ca2. Aliquots were
removed at intervals, diluted 1:10 in ice-cold TBS and assayed for
FVa-procoagulant activity using FV-de¢cient plasma. In this assay,
FV-de¢cient plasma (50 Wl) was incubated with the diluted samples
(50 Wl) at 37‡C for 200 s. Simplastin Excel (100 Wl) was added and the
clotting time recorded. The FVa activity was calculated from a stand-
ard curve constructed with known concentrations of puri¢ed FVa.
2.6. APC-cofactor activity expressed by protein S or the protein S/Gas6
chimera in FVIIIa degradation
The FVIIIa-inhibition assay described by Shen and Dahlbaºck [4] is
used with minor modi¢cations. In the present assay, FVIII (0.05 IU/
ml), FIXa (0.025 IU/ml) and phospholipids (20 WM) were incubated
(in TBS containing 0.2% ovalbumin and 2 mM Ca2) with thrombin
for 3 min. FVIII activation was stopped by the addition of hirudin
and the mixture was put on ice. In the FVIIIa-inhibition step, APC
(4.8 nM) was added to the FVIII-FIXa mixture together with the
indicated concentrations of protein S, or the protein S/Gas6 chimera,
and FV. At the time stated in each experiment, bovine factor X was
added and 6 min later, the generated FXa was measured by 10 min
hydrolysis using S-2222. The amount of FXa that was generated cor-
responded linearly with the FVIIIa activity.
2.7. Statistical analysis
All the results are presented as mean values þ S.E.M. of three in-
dependent experiments performed in duplicate.
3. Results
3.1. Characterization of the protein S/Gas6 chimera
Human recombinant protein S and the protein S/Gas6
chimera (Fig. 1A) were expressed in 293 cells. The fold of
the chimeric protein appears to be correct since the protein
activates members of the Axl subfamily of tyrosine kinase
receptors equally well as intact Gas6 (data not shown). The
same observations with a similar chimera have been reported
by Mark et al. [26]. From SDS-PAGE analysis (Fig. 1B), the
apparent molecular weight of the protein S/Gas6 chimera
(75 kDa) was found to be slightly lower than that of recombi-
nant or plasma-derived protein S (79 kDa). This di¡erence
is explained by the number of N-linked glycosylation sites
present in the SHBG-like region of protein S and Gas6 (three
in protein S and one in Gas6). As expected, the protein
S/Gas6 chimera reacted with the calcium-dependent mono-
clonal antibody HPS21, which is directed against an epitope
in the unreduced protein S Gla domain (Fig. 1C). This
antibody did not react with Gas6. In contrast, both Gas6
and the protein S/Gas6 chimera were recognized by a poly-
clonal antibody against the carboxy-terminal portion of hu-
man Gas6, an antibody which did not react with protein S
(Fig. 1D).
3.2. APC-cofactor activity expressed by the protein S/Gas6
chimera in an APTT system
The ability of recombinant protein S or the protein S/Gas6
chimera to function as cofactors to APC in protein S-de¢cient
plasma was tested using an APTT-based coagulation assay.
Recombinant protein S yielded a dose-dependent prolonga-
tion of clotting time. The protein S/Gas6 chimera was also
able to prolong the clotting time, but less e⁄ciently than
protein S (Fig. 2). The protein S/Gas6 chimera expressed ap-
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proximately 40^50% APC-cofactor activity as compared to
recombinant protein S.
3.3. APC-cofactor activity of the protein S/Gas6 chimera in
FVa degradation
Inactivation of FVa by APC in the presence of physiolog-
ical concentration of either protein S or the protein S/Gas6
chimera was followed as a function of time (Fig. 3). APC
alone, at an enzyme to substrate ratio of 1:100, yielded fast
inhibition of FVa activity, and after 2.5 min of incubation,
less than 50% of the original FVa activity remained. The fast
initial loss of activity was followed by a phase with slower loss
of FVa activity, and even after 15 min incubation, approxi-
mately 20% FVa activity remained. This biphasic inhibition
curve, which is typical for APC-mediated inhibition of FVa in
the absence of protein S, was recently explained by a two-step
inhibition mechanism. The initial fast APC-mediated cleavage
at Arg-506 yields partial loss of FVa activity, whereas the
slow cleavage at Arg-306 results in complete loss of activity
[3]. Protein S is known to enhance the cleavage at Arg-306
[27,28]. Both the recombinant protein S and the protein S/
Gas6 chimera enhanced the second phase of the FVa inacti-
vation, i.e. the cleavage at Arg-306 (Fig. 3). This was demon-
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Fig. 2. APC-cofactor activity of protein S or the protein S/Gas6 chi-
mera in an APTT-based assay. Recombinant human protein S (a)
or the protein S/Gas6 chimera (E) were incubated with protein S-de-
¢cient plasma and APTT reagent for 180 s before the addition of
APC/CaCl2. The prolongation of clotting time is expressed as func-
tion of the concentration of protein S or the protein S/Gas6 chi-
mera in the ¢nal solution. Without added APC cofactors, the clot-
ting time in the absence of APC was 50 s and in its presence, 88 s.
Fig. 1. Characterization of recombinant protein S and the protein S/Gas6 chimera. A: Schematic models of the two recombinant proteins, dem-
onstrating the multiple domains of protein S (in white) or Gas6 (in black). B: Coomassie-stained SDS-polyacrylamide gel of (phPS), plasma
puri¢ed human protein S; (rhPS), recombinant human protein S; and (chimera), protein S/Gas6 chimera (2 Wg of protein is added in each
lane). C: Western blots using antibodies against the Gla domain of human protein S (HPS21) or (D) for the last 25 amino acids of human
Gas6. Conditioned media of cells expressing human Gas6 or from mock-transfected cells were used as controls to test the speci¢city of the anti-
bodies. Abbreviations are as in B. The samples analysed in C were unreduced while those in B and D were treated with reduction agent.
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strated by the faster appearance of a 306 cleavage product
detected by Western blotting (data not shown).
3.4. The protein S/Gas6 chimera expresses no FV-dependent
APC-cofactor activity in the degradation of FVIIIa
Approximately 90% of initial FVIIIa activity remained after
2.5 min inactivation of the FVIIIa-FIXa mixture with APC
alone. This is consistent with results on record, demonstrating
FVIIIa to be a poor substrate for APC alone [4,29,30]. The
addition of protein S or the protein S/Gas6 chimera resulted
in only a small further loss of FVIIIa activity (Fig. 4A). How-
ever, the combined addition of protein S and FV resulted in
e⁄cient APC-dependent inhibition of FVIIIa activity (Fig.
4B,C), demonstrating the synergistic cofactor activity of pro-
tein S and FV. In contrast, in the presence of the protein S/
Gas6 chimera, FV did not stimulate APC-dependent inhibi-
tion of FVIIIa, suggesting the SHBG-like region of protein S
to be crucial for expression of FV-dependent APC-cofactor
function.
4. Discussion
The anticoagulant function of protein S is essential for con-
trol of hemostasis, as illustrated by the life-threatening risk of
thrombosis associated with homozygous protein S de¢ciency
[2]. Despite its clinical and physiological relevance, the molec-
ular mechanism of the protein S function is incompletely
understood. A puzzling observation has been that protein S
seems more active as APC cofactor in plasma, than in FVa-
and FVIIIa-degradation systems using puri¢ed components
[29,31]. A possible explanation for this discrepancy is the ex-
istence of other plasma components a¡ecting the protein S
activity. One such component is FV, which has been found
to enhance APC-mediated inhibition of the FVIIIa-FIXa
complex on the surface of phospholipids [4,30]. The APC-
cofactor activity of FV is particularly pronounced in the pres-
ence of protein S, suggesting a synergistic APC-cofactor ac-
tivity of protein S and FV to be important for the inhibition
of FVIIIa [4^6]. It has been proposed that the APC-cofactor
activity of FV is mainly expressed after APC cleavage of in-
tact FV [29]. In contrast, cleavage of FV by thrombin results
in the loss of its APC-cofactor activity [4]. Recently, using
recombinant FV and site-directed mutagenesis, we demon-
strated the APC-cofactor activity of FV to be lost as a result
of thrombin-mediated cleavage of FV at Arg-1545, whereas
thrombin-mediated cleavages of FV at Arg-709 or Arg-1018
had no e¡ect on the APC-cofactor activity [32]. Moreover, we
found the last 60 amino acid residues of the B-domain of FV
to play an important part in the expression of the APC-co-
factor activity of FV.
It is of interest to compare the functional properties of the
protein S/Gas6 chimera with those of mini-protein S, a dele-
tion mutant of protein S lacking the whole SHBG-like region
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Fig. 4. The e¡ects of protein S and the protein S/Gas6 chimera on
APC-mediated FVIIIa degradation. Incubation was performed either
in the absence or in the presence of FV, as FV works in synergy
with protein S as cofactor in the degradation of FVIIIa. FVIIIa
was degraded for 2.5 min with 4.8 nM APC and di¡erent concen-
trations of either human recombinant protein S (a), or the protein
S/Gas6 chimera (E). A: No FV added to the inactivation mixture.
B: 5 nM FV added. C: 10 nM FV added. The FVIIIa activity was
related to the FVIIIa activity expressed in an inactivation mixture
with APC (with or without FV) and without protein S or the pro-
tein S/Gas6 chimera.
Fig. 3. APC-mediated inactivation of puri¢ed FVa in the presence
of protein S or the protein S/Gas6 chimera. The inhibition of FVa
(30 nM) by APC (0.3 nM) alone (O), in the presence of 120 nM of
either protein S (a) or the protein S/Gas6 chimera (E) was fol-
lowed for various times. The FVa activity was measured by a clot-
ting assay described in Section 2.
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[11]. Although mini-protein S had low APC-cofactor activity
in a plasma-based assay, its activity could not be distinguished
from that of wild-type protein S in the degradation of FVa
and FVIIIa, using puri¢ed components. In this context it is of
importance to note that FV was not included in the FVIIIa-
degradation system used by van Wijnen et al. [11]. Therefore,
conclusions related to the importance of the SHBG-like re-
gion for the synergistic APC-cofactor activities of protein S
and FV could not be drawn.
The low APC-cofactor activity of the protein S/Gas6 chi-
mera and mini-protein S in plasma, is most likely explained by
a lack of APC-cofactor synergy between either of them and
FV. Thus, substitution of the SHBG-like region of protein S
by that of Gas6 completely abolished the anticoagulant e¡ect
of FV in the degradation of FVIIIa. This implies that protein
S/Gas6 chimera did not interact properly with FV and sug-
gests the existence of a speci¢c binding site for FV in the
SHBG-like region of protein S. It has previously been shown
that protein S can bind directly to immobilized FVa (in micro-
titer plates), and with less a⁄nity to FV [33^35]. It is possible
that interactions between protein S and FVa/FV are impor-
tant both for the degradation of FVa and FVIIIa. An inter-
action between FVa and protein S may be involved in FVa
degradation, whereas an interaction between protein S and
FV is important for FVIIIa degradation. In our present in-
vestigation, the FVa degradation was less a¡ected than the
FVIIIa degradation by the SHBG exchange between protein
S and Gas6. Therefore, the now proposed binding site in the
SHBG-like region of protein S is likely speci¢c for FV and not
for fully activated FVa, which is cleaved at Arg1545 and
therefore has no APC-cofactor activity [32].
In conclusion, we demonstrate the SHBG-like region of
protein S to play an important part in the expression of full
APC-cofactor activity. Thus, substitution of the SHBG-like
region of protein S by that of Gas6 resulted in total loss of
the synergistic APC-mediated anticoagulant e¡ect of protein S
and FV, in the degradation of FVIIIa. This suggests the ex-
istence of a speci¢c interaction between FV and the SHBG-
like region of protein S to be important for e⁄cient degrada-
tion of FVIIIa.
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